Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

JAX ‘mighty mice’ are sent into space

Over the course of 40 days on the International Space Station (ISS), researchers will determine the effect of microgravity on JAX’s Mighty Mice — genetically...

| By Kelley Gipson

UConn studies human somatic cell genome editing

Human somatic cell genome editing  is a promising treatment option for cardiovascular disorders, but concerns remain about the safety and efficacy of this therapeutic strategy....

| By Kelley Gipson

NEDP acquired by Genesis Biotechnology Group

Genesis Drug Discovery & Development, a member of Genesis Biotechnology Group, has acquired New England Discovery Partners (NEDP), a Contract Research Organization specializing in synthetic...

| By Kelley Gipson

FDA clears IND for Achillion’s oral factor D inhibitor

Achillion Pharmaceuticals reports that the FDA has reviewed and cleared the Investigational New Drug Application for ACH-5228, the company’s second-generation oral factor D inhibitor. The...

| By Kelley Gipson

Azitra names Jeanne Bertonis Chief Operating Officer

Azitra has appointed Jeanne M. Bertonis Chief Operating Officer. She joins Azitra from Visgo Therapeutics, Inc., a company focused on localized, sustained-release drug delivery, where she was Chief...

| By Kelley Gipson

Thetis receives funding for IBD therapy

Thetis Pharmaceuticals has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to support development of TP-317, a first-in-class, oral therapy for inflammatory bowel...

| By Kelley Gipson

Intensity presents new data re lead product candidate

Intensity Therapeutics presented new data recently re its ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate. INT230-6 is designed for direct...

| By Kelley Gipson

Aeromics to collaborate with Simcere in Greater China

Aeromics has announced a collaboration and exclusive license agreement with China’s Simcere Pharmaceutical Group for Aeromics’ AER-271, a clinical-stage anti-edema therapy, being developed for the...

| By Kelley Gipson

Sema4 appoints Joel Sendek Chief Financial Officer

Sema4 has announced announced the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the...